Millipore Sigma Vibrant Logo

121800 Advanced Glycation Endproduct-BSA

AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells.

Advanced Glycation Endproduct-BSA: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: AGE-BSA

View Products on Sigmaaldrich.com
121800
Ver precios y disponibilidad

Descripción

Replacement Information

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
121800-10MG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Frasco de vidrio 10 mg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewPrepared by reacting BSA with glycoaldehyde under sterile conditions. Glycated-BSA shows a 5,000 - 10,000% increase in fluorescence as compared to normal BSA (confirmed by fluorescence spectrophotometry, excitation/emission 370/440 nm). AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells. Advanced glycation end products and their receptors have been implicated in the pathogenesis of diabetes, induction of proinflammatory cytokines, and stimulation of smooth muscle proliferation, and fibronectin production.
      Catalogue Number121800
      Brand Family Calbiochem®
      SynonymsAGE-BSA
      References
      ReferencesOkamoto, T., et al. 2002. Microvasc. Res. 63, 186.
      Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
      Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
      Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
      Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
      Farboud, B., et al. 1999. Mol. Vis. 5, 11.
      Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
      Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
      Neumann, A., et al. 1999. FEBS Lett. 453, 283.
      Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
      Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.
      Product Information
      FormLiquid
      FormulationIn sterile-filtered PBS.
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by SDS-PAGE
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Standard Handling
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      121800-10MG 04055977206197

      Documentation

      Licencias necesarias

      Título
      PRODUCTO REGULADO POR LA SAGARPA
      PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

      Advanced Glycation Endproduct-BSA Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Advanced Glycation Endproduct-BSA Certificados de análisis

      CargoNúmero de lote
      121800

      Referencias bibliográficas

      Visión general referencias
      Okamoto, T., et al. 2002. Microvasc. Res. 63, 186.
      Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
      Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
      Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
      Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
      Farboud, B., et al. 1999. Mol. Vis. 5, 11.
      Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
      Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
      Neumann, A., et al. 1999. FEBS Lett. 453, 283.
      Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
      Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.

      Folleto

      Cargo
      Caspases and other Apoptosis Related Tools Brochure
      Pathways and Biomarkers of Oxidative Stress
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision08-April-2008 RFH
      SynonymsAGE-BSA
      DescriptionPrepared by reacting bovine serum albumin (BSA) with glycoaldehyde under sterile conditions. Fluorescence of AGE-BSA is confirmed by fluorescence spectrophotometry, excitation/emission = 370/440 nm. Glycated BSA shows a 5000-10,000% increase in fluorescence compared to control BSA. AGE and their receptors have been implicated in the pathogenesis of diabetes, induction of pro-inflammatory cytokines, and stimulation of smooth muscle proliferation and fibronectin production. AGE-BSA has also been shown to induce apoptosis in cultured human umbilical vein endothelial cells (HUVEC) and inhibit nitric oxide synthase activity in proximal tubular epithelial cells of the kidney.
      FormLiquid
      FormulationIn sterile-filtered PBS.
      Concentration Label Please refer to vial label for lot-specific concentration
      Purity≥95% by SDS-PAGE
      Storage Avoid freeze/thaw
      ≤ -70°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
      Toxicity Standard Handling
      ReferencesOkamoto, T., et al. 2002. Microvasc. Res. 63, 186.
      Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
      Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
      Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
      Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
      Farboud, B., et al. 1999. Mol. Vis. 5, 11.
      Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
      Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
      Neumann, A., et al. 1999. FEBS Lett. 453, 283.
      Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
      Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.